142 related articles for article (PubMed ID: 8780544)
1. Pretherapeutic erythrocyte polyamine spermine levels discriminate high risk relapsing patients with M1 prostate carcinoma.
Cipolla BG; Ziade J; Bansard JY; Moulinoux JP; Staerman F; Quemener V; Lobel B; Guillé F
Cancer; 1996 Sep; 78(5):1055-65. PubMed ID: 8780544
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment serum level of HER2/nue as a prognostic factor in metastatic prostate cancer patients about to undergo endocrine therapy.
Okegawa T; Kinjo M; Nutahara K; Higashihara E
Int J Urol; 2006 Sep; 13(9):1197-201. PubMed ID: 16984552
[TBL] [Abstract][Full Text] [Related]
3. External beam radiotherapy for clinically node-negative, localized hormone-refractory prostate cancer: impact of pretreatment PSA value on radiotherapeutic outcomes.
Akimoto T; Kitamoto Y; Saito J; Harashima K; Nakano T; Ito K; Yamamoto T; Kurokawa K; Yamanaka H; Takahashi M; Mitsuhashi N; Niibe H
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):372-9. PubMed ID: 15145150
[TBL] [Abstract][Full Text] [Related]
4. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
5. The prognostic value of erythrocyte polyamine in the post-nephrectomy stratification of renal cell carcinoma specific mortality.
Bigot P; Lughezzani G; Karakiewicz P; Perrotte P; Rioux-Leclercq N; Catros-Quemener V; Bouet F; Moulinoux JP; Cipolla B; Patard JJ
J Urol; 2010 Feb; 183(2):486-91. PubMed ID: 20006872
[TBL] [Abstract][Full Text] [Related]
6. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
7. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
[TBL] [Abstract][Full Text] [Related]
8. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas.
Stege R; Grande M; Carlström K; Tribukait B; Pousette A
Clin Cancer Res; 2000 Jan; 6(1):160-5. PubMed ID: 10656445
[TBL] [Abstract][Full Text] [Related]
11. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
[TBL] [Abstract][Full Text] [Related]
12. Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival.
Cheville JC; Tindall D; Boelter C; Jenkins R; Lohse CM; Pankratz VS; Sebo TJ; Davis B; Blute ML
Cancer; 2002 Sep; 95(5):1028-36. PubMed ID: 12209687
[TBL] [Abstract][Full Text] [Related]
13. [The diagnostic value of erythrocyte polyamines (EPA) in prostatic adenocarcinoma (PA): apropos of 100 patients].
Cipolla B; Guille F; Quemener V; Lévêque JM; Moulinoux JP; Lobel B
Prog Urol; 1992 Feb; 2(1):50-7. PubMed ID: 1284385
[TBL] [Abstract][Full Text] [Related]
14. Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors.
Park SC; Rim JS; Choi HY; Kim CS; Hong SJ; Kim WJ; Lee SE; Song JM; Yoon JH
Int J Urol; 2009 Aug; 16(8):670-5. PubMed ID: 19602007
[TBL] [Abstract][Full Text] [Related]
15. Erythrocyte polyamines and prognosis in stage D2 prostatic carcinoma patients.
Cipolla B; Guille F; Moulinoux JP; Bansard JY; Roth S; Staerman F; Corbel L; Quemener V; Lobel B
J Urol; 1994 Mar; 151(3):629-33. PubMed ID: 7508520
[TBL] [Abstract][Full Text] [Related]
16. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
17. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
Fujii Y; Kawakami S; Masuda H; Kobayashi T; Hyochi N; Kageyama Y; Kihara K
BJU Int; 2006 Jun; 97(6):1184-9. PubMed ID: 16686709
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
[TBL] [Abstract][Full Text] [Related]
19. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era.
Zagars GK; Pollack A; von Eschenbach AC
Cancer; 1997 Apr; 79(7):1370-80. PubMed ID: 9083160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
